Neuronetics (STIM) Misses Q2 EPS by 6c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Neuronetics (STIM) PT Lowered to $3 at Canaccord Genuity
August 13, 2024 6:23 AM EDTCanaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $3.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Bottom line: STIMs Q2/24 missed estimates with $16.5M of revenue, driven by low treatment session revenue as customers delayed refilling inventory due to continued prior authorization and reimbursement headwinds from Change Healthcares cybersecurity breach impacting STIMs customer base. That said, STIM reiterated its FY24 revenue guidance of $78M-$80M, displaying confidence in the... More
